Ongoing advancements with multiple sclerosis (MS) care can make it challenging for providers to frequently adapt their practice. In addition, recent evidence has highlighted the complexity of optimizing therapy for individual patients throughout their care journey. How up to date are you with the new and emerging MS therapies? How comfortable are you with applying the data in routine practice? Join us for this 45-minute video, presented by MS experts to help you stay at the forefront of MS treatment and make a tangible difference in patient care. Features of this program include: examining clinical data for approved and investigational therapies for patients with relapsing and progressive forms of MS review of the safety and efficacy considerations of disease-modifying therapies strategies for translating evidence into clinical practice discussion of patient cases and key takeaways from a recent project ECHO initiative. Participants will also have access to a downloadable pocket guide that will highlight key items for treatment selection, including prognostic factors, monitoring treatment response, and patient individualization.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/efficacy-safety-new-emerging-dmts-translating-clinical-trial
- Start Date: 2024-08-28 05:00:00
- End Date: 2024-08-28 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 1666.67 - Is Kind Support: False Source: Genentech (Any division) - Amount: 28250.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 24916.67 - Is Kind Support: False Source: Viatris - Amount: 28250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all